StatPearls-/-ä 2024[Jan]; ä (ä): ä PMID34283469show ga
As of January 24, 2022, the United States Food and Drug Associated (FDA) fact-sheet for the drug etesevimab states that "due to the high frequency of the Omicron variant, bamlanivimab and etesevimab, administered together, are not currently authorized for use in any U.S. region because of markedly reduced activity against the Omicron variant. These drugs may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the Agency." This article is for historical purposes only to review the indications, mechanism, and administration of this therapy when it was first developed.